[{"id":"8a97b982-1080-4569-8eba-1344e2c2a7e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01889407","created_at":"2021-01-18T08:28:59.012Z","updated_at":"2024-07-02T16:37:39.643Z","phase":"","brief_title":"Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients","source_id_and_acronym":"NCT01889407","lead_sponsor":"Nanfang Hospital of Southern Medical University","biomarkers":" ABCB1 • WT1 • GAPDH","pipe":" | ","alterations":" ABCB1 overexpression","tags":["ABCB1 • WT1 • GAPDH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABCB1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • idarubicin hydrochloride"],"overall_status":"Unknown status","enrollment":" Enrollment 94","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2015-04-21"}]